Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Evaluation of Revumenib in Participants With Colorectal Cancer and Other Solid Tumors
NCT05731947 · Syndax Pharmaceuticals · PHASE1/PHASE2 · terminated · last registry update 2026-07-06 · Colorectal cancer · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Study was terminated by sponsor after Phase 1b as pre-defined signals of efficacy were not met in the Phase 1b dose expansion cohort.” | Open Targets' class: negative | Registry record, Syndax Pharmaceuticals |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against MEN1 in colorectal cancer within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
No results, stops or Phase 3 starts on the same target in that window.
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision